Stay updated with breaking news from Processa Pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) CEO David Young bought 40,000 shares of Processa Pharmaceuticals stock in a transaction that occurred on Monday, June 12th. The shares were acquired at an average cost of $0.80 per share, for a total transaction of $32,000.00. Following the completion of the transaction, the chief executive officer now […]
The Dow Jones closed higher by around 190 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) shares shot up 2.6% during mid-day trading on Tuesday . The company traded as high as $0.57 and last traded at $0.56. 35,908 shares changed hands during mid-day trading, a decline of 82% from the average session volume of 201,922 shares. The stock had previously closed at $0.55. […]
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) shares shot up 2.6% during mid-day trading on Tuesday . The company traded as high as $0.57 and last traded at $0.56. 35,908 shares changed hands during mid-day trading, a decline of 82% from the average session volume of 201,922 shares. The stock had previously closed at $0.55. […]
22.05.2023 - Company also to provide a corporate overview in a separate session HANOVER, MD, May 22, 2023 (GLOBE NEWSWIRE) - Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on ...